Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.

Connick, Peter; Kolappan, Madhan; Crawley, Charles; Webber, Daniel J; Patani, Rickie; Michell, Andrew W; Du, Ming-Qing; Luan, Shi-Lu; Altmann, Daniel R; Thompson, Alan J; +4 more... Compston, Alastair; Scott, Michael A; Miller, David H; Chandran, Siddharthan; (2012) Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet neurology, 11 (2). pp. 150-156. ISSN 1474-4422 DOI: https://doi.org/10.1016/S1474-4422(11)70305-2

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S1474-4422(11)70305-2

Abstract

Share

Download

Filename: 1-s2.0-S1474442211703052-main-1.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar